[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619316":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":37,"collaborators":7,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":41,"sex":47,"minAge":48,"maxAge":7,"enrollmentInfo":49,"targetDuration":7,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"University Hospital, Strasbourg, France","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Antonin HUGEROT, MD","CONTACT","33 3 88 12 79 24","antonin.hugerot@chru-strasbourg.fr",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Médecine intensive - Réanimation - CHU de Strasbourg - France","RECRUITING","Strasbourg","67091","France","FR",{"type":23,"coordinates":24},"Point",[25,26],7.74553,48.58392,{"lat":26,"lon":25},[29,30,32,35],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":10,"role":31,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"name":33,"role":34,"phone":7,"phoneExt":7,"email":7},"Antoine CHANZY, MD","SUB_INVESTIGATOR",{"name":36,"role":34,"phone":7,"phoneExt":7,"email":7},"Vincent CASTELAIN, MD, PhD",{"type":38,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100619316","diagnosis-of-lymphohistiocytic-hemophagocytosis-in-intensive-care-100619316",false,"NCT07343037","Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care","Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care: Relevance of the Hscore and Search for the Best Diagnostic Markers","SAMICU","Inclusion Criteria:\n\n* Adult patient (≥18 years old)\n* Patient admitted to the intensive care unit at Hautepierre Hospital, Strasbourg University Hospital, between January 1, 2014, and December 31, 2024\n* At least 3 biological signs of HLH:\n\n  * ferritin \\> 2000 ng\u002FmL\n  * triglycerides \\> 1.5 g\u002FL\n  * at least one cytopenia (leukocytes ≤ 5000 G\u002FL, platelets ≤ 110 G\u002FL, hemoglobin ≤ 9.2 g\u002FdL).\n\nExclusion Criteria:\n\nRefusal to participate in the study","ALL","18 Years",{"count":50,"type":51},100,"ESTIMATED","OBSERVATIONAL","Patients with hepatocellular insufficiency and\u002For cirrhosis are at risk of developing invasive fungal infections, particularly in critical care settings.\n\nIn international recommendations, voriconazole is positioned as the first-line treatment for invasive aspergillosis. However, this molecule-and the azole class of antifungals-is associated with frequent hepatic toxicity. Available since 2018, isavuconazole appears to be better tolerated in patients without pre-existing liver dysfunction.\n\nThe aim of this study is to retrospectively evaluate the validity of the hscore in intensive care and resuscitation patients.",[55,56],"Hepatic Insufficiency","Cirrhosis, Liver",[55,56,58,59,60,61,62],"Lymphohistiocytic hemophagocytosis","Hepatocellular insufficiency","Invasive aspergillosis","Azole antifungals","Liver dysfunction.","2026-01-06",{"date":65,"type":66},"2026-01-15","ACTUAL",{"date":68,"type":66},"2025-08-29",{"date":70,"type":51},"2026-08-29",{"name":5,"class":6},1]